X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Through the acquisition, Lilly expands its oncology capabilities into next-generation radioligand therapies by including PNT2002 (177Lu-PNT2002), a PSMA targeted radioligand therapy in development for patients with metastatic castration-resistant prostate cancer.
Lead Product(s): 177Lu-PNT2002
Therapeutic Area: Oncology Product Name: PNT2002
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: $1,400.0 million Upfront Cash: $1,400.0 million
Deal Type: Acquisition December 27, 2023
Details:
Through the acquisition, Lilly expands its oncology capabilities into next-generation radioligand therapies by including PNT2002 (177Lu-PNT2002), a PSMA targeted radioligand therapy in development for patients with metastatic castration-resistant prostate cancer.
Lead Product(s): 177Lu-PNT2002
Therapeutic Area: Oncology Product Name: PNT2002
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: $1,400.0 million Upfront Cash: $1,400.0 million
Deal Type: Acquisition October 03, 2023
Details:
The expanded agreement broadens the supply of ITM’s n.c.a. 177Lu to POINT to enable its usage in the clinical and potential future commercial development of the 177Lu-based molecules in POINT’s development pipeline, including 177Lu-PNT2002 for prostate cancer.
Lead Product(s): 177Lu-PNT2002
Therapeutic Area: Oncology Product Name: PNT2002
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Point Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 31, 2023
Details:
PNT2002 (Lu-177-PSMA-I&T) is a PSMA-Targeted therapy for metastatic castration-resistant prostate cancer (mCRPC). PNT2002 combines a PSMA-targeted ligand, PSMA-I&T, with the beta-emitting radioisotope lutetium-177.
Lead Product(s): 177Lu-PNT2002
Therapeutic Area: Oncology Product Name: PNT2002
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Lantheus Holding
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 24, 2023
Details:
PNT2002 (Lu-177-PSMA-I&T) is a PSMA-Targeted therapy for metastatic castration-resistant prostate cancer (mCRPC). PNT2002 combines a PSMA-targeted ligand, PSMA-I&T, with the beta-emitting radioisotope lutetium-177.
Lead Product(s): 177Lu-PNT2002
Therapeutic Area: Oncology Product Name: PNT2002
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 12, 2023
Details:
PNT2002 (Lu-177-PSMA-I&T) is a PSMA-Targeted therapy for metastatic castration-resistant prostate cancer (mCRPC). PNT2002 combines a PSMA-targeted ligand, PSMA-I&T, with the beta-emitting radioisotope lutetium-177.
Lead Product(s): 177Lu-PNT2002
Therapeutic Area: Oncology Product Name: PNT2002
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Lantheus Holdings
Deal Size: $2,115.0 million Upfront Cash: $260.0 million
Deal Type: Agreement December 20, 2022
Details:
Lu-177-PSMA-I&T (Lu-177-PNT2002) is a PSMA-Targeted therapy for mCRPC. PSMA is overexpressed in the vast majority of prostate cancers, but very limited to normal tissues. PNT2002 combines a PSMA-targeted ligand, PSMA-I&T, with the beta-emitting radioisotope lutetium-177.
Lead Product(s): 177Lu-PNT2002
Therapeutic Area: Oncology Product Name: 177Lu-PSMA-I&T
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Lantheus Holding
Deal Size: $2,115.0 million Upfront Cash: $260.0 million
Deal Type: Collaboration November 14, 2022
Details:
POINT intends to use the net proceeds from the proposed offering, to fund clinical and preclinical research and development programs including PNT2002 (Lu-177-PSMA-I&T), pre-commercialization activities, and for working capital and other general corporate purposes.
Lead Product(s): 177Lu-PNT2002
Therapeutic Area: Oncology Product Name: PNT2002
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Piper Sandler
Deal Size: $13.9 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 16, 2022
Details:
POINT intends to use the net proceeds from the proposed offering, to fund clinical and preclinical research and development programs including PNT2002, pre-commercialization activities, and for working capital and other general corporate purposes.
Lead Product(s): 177Lu-PNT2002
Therapeutic Area: Oncology Product Name: PNT2002
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Piper Sandler
Deal Size: $125.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 13, 2022
Details:
Key findings for PNT2002 (Lu-177-PSMA-I&T), include a median rPFS time of 11.5 months, along with a well-tolerated safety profile with no treatment-related deaths and few treatment-related AEs of grade 3 or higher.
Lead Product(s): 177Lu-PNT2002
Therapeutic Area: Oncology Product Name: PNT2002
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 09, 2022
Details:
PNT2002 (Lu-177-PSMA-I&T) is a PSMA-Targeted therapy for metastatic castration-resistant prostate cancer (mCRPC),is overexpressed in the vast majority of prostate cancers (>85%), but very limited to normal tissues.
Lead Product(s): 177Lu-PNT2002
Therapeutic Area: Oncology Product Name: PNT2002
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 18, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
